Antihypertensives Dominate The Chronic Kidney Disease Drugs Market
The global chronic kidney disease drugs market is expected to witness a CAGR of 4.1% to reach revenue of $16.6 billion by 2025
Bangalore, India, March 25, 2019: With its recently published study “Global Chronic Kidney Disease Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global market for chronic kidney disease drugs is expected to witness single-digit growth during 2019–2025. The drug pipeline of chronic kidney disease looks promising with novel therapeutic approaches, such as cell therapy, likely to enhance the market growth opportunities. However, the competition from biosimilars and complex drug development processes are impeding the market growth.
Over the period, extensive research is being done to fill the unmet needs’ gap. The advances in the arena of regenerative treatment have come up with budding advancement of cell therapies that help regeneration and repairing of the kidneys. Cell therapy is proficient of refining the fundamental functioning capability of the kidney. Uncontrolled high blood pressure and diabetes are the leading causes of kidney failure globally.
Get a Sample Copy of the Report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=13335
North America dominates the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market is from the US. In the US, CKD implies an enormous cost burden, costing Medicare about $65 billion annually for CKD care and management, and an additional $34 billion associated with patients for dialysis care. Asia Pacific is projected to offer lucrative growth opportunities to market players on the grounds of the rising expenditure on healthcare, infrastructural advancements in the healthcare industry, and the growing focus on community healthcare.
Access Full Report Summary @ https://www.infoholicresearch.com/report/chronic-kidney-disease-drugs-market
“The market is growing at a flat rate, with a single-digit CAGR during the forecast period. Government establishments and market players are taking various initiatives to increase awareness. Campaigns are conducted globally to encourage people in adopting healthy lifestyles. For instance, in May 2018, Baxter partnered with the International Society of Nephrology to increase awareness and therapy for patients with CKD in low and middle-income countries. Exhaustive pipeline for chronic kidney disease drugs is promising the market growth in the future. ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied in Phase III clinical trials in the US, Europe, China, and Japan. Dapagliflozin by AstraZeneca is presently in phase III to assess the effect of dapagliflozin on renal products and cardiovascular mortality in individuals with chronic kidney disease (Dapa-CKD).” – Rikitha K Murthy, Research Analyst, Infoholic Research
Key Insights of the Report Include:
- Drug Class:
- Erythropoiesis-stimulating agents (ESAs)
- Specialty Clinics
- Industry outlook: Market trends, drivers, restraints, and opportunities